

## Instructions for Authors 2015

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures should appear inline in the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

*Tables.* All tables should appear inline in the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions to authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2014): 65%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

# CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**. For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

## A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland*)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (*Beijing, China; Cardiff, UK*)

TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (*Penzberg, Germany*)

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*)

Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (*Boca Raton, FL, USA*)

Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA (*Tokyo, Japan*)

Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (*Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia*)

Metabolic profile of Triple-negative Breast Cancer in African-American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. ESNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND, E. GABRIELSON, R.L. DEWITTY JR. (*Washington DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA*)

Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)

The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (*Bucharest, Romania; Charlestown, MA, USA*)

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)

## Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor- $\beta$ 1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (*Loma Linda, CA; Winston-Salem, NC, USA*)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (*Omaha, NE; Ocala, FL, USA*)

Organ-specific Responses of Total Body Irradiated Doxycycline-inducible Manganese Superoxide Dismutase Tet/Tet Mice. B.H. RHIEU, A. SHINDE, M.W. EPPERLY, T. DIXON, H. WANG, R. CHAILLET, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effect of GPIIb/IIIa Inhibition with Eptifibatid or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (*Heidelberg; Tuebingen; Kirchheim; Solingen, Germany*)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilament-directed Agents in Tumor Model Systems *In Vivo*. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (*Syracuse, NY, USA*)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (*Columbus, OH; San Juan Capistrano, CA, USA*)

Efficacy and Side Effects of a Semi-individualized Chinese Herb Mixture "Tiáo Gēng Tāng" for Menopausal Syndrome in China. M. JIA, L. KLUWE, H.-C. LIU, Q.-J. TANG, L. LIU, Z.-Z. WANG, L.-X. TIAN, L. ZHAO, Y.-C. CHEN, R.E. FRIEDRICH, Z.-J. SUN, L.-W. XU (*Shanghai, PR China; Hamburg, Germany*)

Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (*Jackson, MS, USA*)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKKESFELDT, J. ROSENBERG, I. GÖGENUR (*Køge; Copenhagen; Herlev, Denmark*)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIOKOSKI, D. SAJUTHI, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada*)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (*Tokyo; Saitama; Aichi, Japan*)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUJIKAWA, A. TANAKA (*Kobe; Osaka; Suita; Kainan, Japan*)

CAG-repeats in Androgen Receptor Gene Relate with Plasma Androgens Levels in the Bouvier Des Flandres. H. L' EPLATTENIER, E. TESKE, F. VAN SLUIJS, J.A. MOL (*Utrecht, Netherlands*)

Bone Substitutes Enhance Osteogenic Differentiation of Mesenchymal Stem Cells in Three-dimensional Scaffolds. H. HANKEN, J. ALPERS, M. BÖBEL, M. WÖLTJE, P. HARTJEN, R.E. FRIEDRICH, O. JUNG, C. RENDENBACH, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, R. SMEETS (*Hamburg; Aachen, Germany*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

# Subscription Order Form 2015

- Please enter a Subscription to ANTICANCER RESEARCH Volume 35 (2015).  
Annual subscription rates (2015): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;  
Prices include rapid delivery and insurance.  
2015 online subscriptions include free online access to vol. 24 (2004) - 34 (2014).
- Please send me the following previous volumes (1-34) at 50% discount on the above rates.
- Payment is enclosed.  Please invoice.  
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .....

Tel: .....

Fax: ..... e-mail: .....

Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

## Special 2015 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2015 on a basis of priority and availability. Effective from January to December 2015).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**

Please complete and send this order form to:  
ANTICANCER RESEARCH, International Institute of Anticancer Research,  
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2014
- 34 volumes
- over 116,000 pages
- over 16,900 original articles
- 834 reviews
- over 75,200 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

### Special Subscription Order Form 2015

- I am one of the authors of the article published in Anticancer Research Vol....., pp. ...., year .....
- Please enter my personal subscription to Anticancer Research 2015 (Volume 35) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) ..... at Euro 195.00 (print) per volume.
- Please enter my personal combined 2015 subscription to Anticancer Research (Volume 35) and IN VIVO (Volume 29) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.  
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: .....

Tel-Fax: .....

e-mail: .....

Date and signature: .....

Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11). H.J. PARK, A.R. CHANG, Y. SEO, C.K. CHO, W.-I. JANG, M.S. KIM, C. CHOI ( <i>Seoul; Busan, Republic of Korea</i> ) .....	5103
Pathological Characteristics of Both Tumors in Bifocal and Bicentric Breast Cancer. R. MOSBAH, R. ROUZIER, J.-M. GUINEBRETIERE, M.-C. FALCOU, D. STEVENS, D. HÉQUET ( <i>St Cloud; Montigny-le-Bretonneux; Paris, France</i> ) .....	5111
The Role of PET [ <sup>18</sup> F]FDOPA in Evaluating Low-grade Glioma. V. VILLANI, C.M. CARAPPELLA, A. CHIARAVALLOTI, I. TERRENATO, F. PILUDU, A. VIDIRI, O. SCHILLACI, R. FLORIS, S. MARZI, A. FABI, A. PACE ( <i>Rome; Pozzilli, Italy</i> ) .....	5117
Impact of Hepatitis B Virus on Clinicopathological Features and Outcomes After Resection for Pancreatic Adenocarcinoma. T. DUMITRASCU, P. PINEAU, S. DIMA, C. STROESCU, V. BRASOVEANU, V. HERLEA, M. IONESCU, I. POPESCU ( <i>Bucharest, Romania; Paris, France</i> ) .....	5123
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study. M. NINKOVIC, M. FIEGL, M. MIAN, P. MONDELLO, F. KOCHER, C. WALDTHALER, I. VERDORFER, M. STEURER, G. GASTL, A. PIRCHER ( <i>Innsbruck, Austria; Bolzano; Messina, Italy</i> ) .....	5129
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients. P. DIAMANTOPOULOS, K. ZERVAKIS, V. PAPADOPOULOU, T. ILIAKIS, F. KALALA, N. GIANNAKOPOULOU, N. ROUGALA, A. GALANOPOULOS, P. BAKARAKOS, E. VARIAMI, A. DIMITRAKOPOULOU, N.-A. VINIOU ( <i>Athens, Greece</i> ) .....	5141

Comparative Study Between Total Laparoscopic and Total Robotic Radical Hysterectomy for Cervical Carcinoma: Clinical Study. J.Y. KIM, Y.H. LEE, G.O. CHONG, Y.S. LEE, Y.L. CHO, D.G. HONG ( <i>Daegu, Republic of Korea</i> ) .....	5015
Laparoscopic Total Gastrectomy for RGC: Four Case Reports. S. KOREHISA, K. OHGAKI, T. YUKAYA, Y. ZAITU, Y. TSUDA, Y. KASAGI, K. ANDO, Y. NAKASHIMA, Y. IMAMURA, H. SAEKI, E. OKI, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	5023
Combination of Juvenile Papillomatosis, Juvenile Fibroadenoma and Intraductal Carcinoma of the Breast in a 15-Year-old Girl. T. SEDLOEV, A. BASSAROVA, K. ANGELOV, M. VASILEVA, Y. ASENOV ( <i>Sofia, Bulgaria; Oslo, Norway</i> ).....	5027
Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study. Y. KITAGAWA, S. URATA, A. MIZOKAMI, K. NAKASHIMA, K. KOSHIDA, T. NAKASHIMA, K. MIYAZAKI, M. NAMIKI ( <i>Kanazawa, Ishikawa, Japan</i> ) .....	5031
Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, H. OHTANI, K. SAKURAI, S. YAMAZOE, K. KIMURA, T. TOYOKAWA, R. AMANO, N. KUBO, H. TANAKA, K. MUGURUMA, M. OHIRA, K. HIRAKAWA ( <i>Osaka, Japan</i> ).....	5037
Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis. W.I. JANG, M.-S. KIM, J.S. LIM, H.J. YOO, Y.S. SEO, C.J. HAN, S.C. PARK, C.S. KAY, M. KIM, H.S. JANG, D.S. LEE, A.R. CHANG, H.J. PARK ( <i>Seoul, Republic of Korea</i> ) .....	5047
Amplification of <i>FGFR2</i> Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance. H. SHOJI, Y. YAMADA, N. OKITA, A. TAKASHIMA, Y. HONMA, S. IWASA, K. KATO, T. HAMAGUCHI, Y. SHIMADA ( <i>Tokyo, Japan</i> ) .....	5055
Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond—Preliminary Results. T. TÓKÉS, G. SZENTMÁRTONI, L. TORGYÍK, K. SOMLAI, J. KULKA, Z. LENGYEL, T. GYÖRKE, M. DANK ( <i>Budapest, Hungary</i> ) .....	5063
Large Colorectal Carcinoma Is Predictive of Recurrence After Adjuvant Chemotherapy Using Oxaliplatin. H. NOZAWA, T. NISHIKAWA, T. TANAKA, J. TANAKA, T. KIYOMATSU, K. KAWAI, K. HATA, S. KAZAMA, H. YAMAGUCHI, S. ISHIHARA, E. SUNAMI, J. KITAYAMA, T. WATANABE ( <i>Tokyo, Japan</i> ) .....	5073
Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. K. FURUKAWA, H. SHIBA, Y. SHIRAI, T. HORIUCHI, R. IWASE, K. HARUKI, Y. FUJIWARA, T. MISAWA, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	5079
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. L.L. MICHEL, J.L. BERMEJO, A. GONDOS, F. MARMÉ, A. SCHNEEWEISS ( <i>Heidelberg, Germany</i> ).....	5085
Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer. P. HABEL, A. KURRECK, C.-O. SCHULZ, A.C. REGIERER, D. KAUL, C.W. SCHOLZ, C. NEUMANN, K. POSSINGER, J. EUCKER ( <i>Berlin, Germany</i> ) .....	5091
Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer. N. BACALBASA, I. BAILESCU, S. DIMA, V. BRASOVEANU, I. POPESCU ( <i>Bucharest, Romania</i> ) .....	5097

Impact of Itraconazole After First-line Chemotherapy on Survival of Patients with Metastatic Biliary Tract Cancer. H. TSUBAMOTO, T. SONODA, S. IKUTA, S. TANI, K. INOUE, N. YAMANAKA ( <i>Nishinomiya, Hyogo; Kobe, Japan</i> ) .....	4923
Two Phenotypes of Traditional Serrated Adenomas Nationwide Survey in Iceland. C.A. RUBIO, J.G. JÓNASSON ( <i>Stockholm, Sweden; Reykjavik, Iceland</i> ) .....	4929
Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals. I.J. CHRISTENSEN, N. BRÜNNER, B. DOWELL, G. DAVIS, H.J. NIELSEN, G. NEWSTEAD, D. KING ( <i>Copenhagen; Frederiksberg; Hvidovre, Denmark; Chicago, IL, USA; Randswick; Kogarah, NSW, Australia</i> ) .....	4935
Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix. C. HONORÉ, F. CARUSO, P. DARTIGUES, L. BENHAIM, M. CHIRICA, D. GOÉRE, D. ELIAS ( <i>Villejuif, France</i> ) .....	4943
Facial Basal Cell Carcinomas in Elderly Frail Patients Treated with Low Total-dose Radiotherapy. E.G. RUSSI, A. PELISSERO, A. MELANO, C. FILLINI, R. VIGNA-TAGLIANTI, L. GIANELLO, F. LUCIO, N. SETTINERI, A. SANTACATERINA, A. PONTORIERO, G. IATÌ, S. PERGOLIZZI ( <i>Cuneo; Messina, Italy</i> ).....	4949
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. J. KERSCHBAUMER, F.A. SCHMIDT, A.E. GRAMS, M. NOWOSIELSKI, D. PINGGERA, K.R. BRAWANSKI, O. PETR, C. THOMÉ, J. TUETTENBERG, M. SEIZ, C.F. FREYSCHLAG ( <i>Innsbruck, Austria; Idar-Oberstein; Mannheim, Germany</i> ) .....	4955
Preoperative Change in Peripheral Blood Monocyte Count May Predict Long-term Outcomes After Pancreaticoduodenectomy for Bile Duct Cancer. K. HARUKI, H. SHIBA, T. HORIUCHI, Y. SHIRAI, R. IWASE, Y. FUJIWARA, K. FURUKAWA, T. MISAWA, K. YANAGA ( <i>Tokyo, Japan</i> ).....	4961
Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast Cancer. E. VALICSEK, R. KÓSZÓ, Á. DOBI, G. UHERCSÁK, Z. VARGA, A. VASS, É. JEBELOVSZKY, Z. KAHÁN ( <i>Szeged, Hungary</i> ) .....	4967
Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotype to Gastric Cancer Risk in Taiwan. H.-X. JI, W.-S. CHANG, C.-W. TSAI, J.-Y. WANG, N.-K. HUANG, A.-S. LEE, M.-Y. SHEN, W.-Y. CHEN, Y.-C. CHIANG, T.-C. SHIH, C.-M. HSU, D.-T. BAU ( <i>Taichung; Taipei; New Taipei, Taiwan, ROC</i> ) .....	4975
Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis. Y. KIM, J. WEI, J. CITRONBERG, T. HARTMAN, V. FEDIRKO, M. GOODMAN ( <i>Atlanta, GA; Baltimore, MD; Chapel Hill, NC; Seattle, WA, USA</i> ) .....	4983
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer. J.-M. CLASSE, O. GLEHEN, E. DECULLIER, J.M. BEREDER, S. MSIKA, G. LORIMIER, K. ABOUD, P. MEEUS, G. FERRON, F. QUENET, F. MARCHAL, S. GOUY, C. POMEL, M. POCARD, F. GUYON, N. BAKRIN ( <i>Saint-Herblain; Villeurbanne; Pierre-Bénite; Lyon; Nice; Colombes; Angers; Saint-Priest-en-Jarez; Laennec; Toulouse; Montpellier; Vandoeuvre-lès-Nancy; Villejuif; Clermont-Ferrand; Paris; Bordeaux, France</i> ) .....	4997
Pentafecta Outcomes of 230 Cases of Robotic-assisted Radical Prostatectomy with Bilateral Neurovascular Bundle Preservation. Y.-C. OU, C.-K. YANG, H.-M. KANG, K.-S. CHANG, J. WANG, S.-W. HUNG, M.-C. TUNG, A.K. TEWARI, V.R. PATEL ( <i>Taichung; Taipei, Taiwan, ROC; New York, NY; Orlando, FL, USA</i> ) .....	5007

Radiation Therapy for Para-Aortic Lymph Node Metastasis from Uterine Cervical Cancer. M. HATA, E. MIYAGI, I. KOIKE, R. NUMAZAKI, M. ASAI-SATO, T. KASUYA, H. KAIZU, Y. MUKAI, F. HIRAHARA, T. INOUE ( <i>Yokohama, Kanagawa, Japan</i> ) .....	4849
PHI in the Early Detection of Prostate Cancer. R. FUCHSOVA, O. TOPOLCAN, J. WINDRICOVA, M. HORA, O. DOLEJSOVA, L. PECEN, P. KASIK, J. NOVAK, M. CASOVA, J. SMEJKAL ( <i>Pilsen, Czech Republic</i> ) .....	4855
Comparison of Neoadjuvant Chemotherapy to Surgery Followed by Adjuvant Chemotherapy in Japanese Patients with Peritoneal Lavage Cytology Positive for Gastric Carcinoma. M. YAMAMOTO, H. KAWANO, S. YAMAGUCHI, A. EGASHIRA, K. MINAMI, K. TAGUCHI, Y. IKEDA, M. MORITA, Y. TOH, T. OKAMURA ( <i>Minami-ku, Fukuoka, Japan</i> ) .....	4859
Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery. S. MORINAGA, M. MURAKAWA, Y. KATAYAMA, K. YAMAOKU, T. AOYAMA, A. KANAZAWA, A. HIGUCHI, M. SHIOZAWA, S. KOBAYASHI, M. UENO, M. MORIMOTO ( <i>Asahiku, Yokohama, Japan</i> ) .....	4865
Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression. J. BOSCH-BARRERA, F. HOLGUIN, X. BALDÓ, M. RUBIO, R. PORTA, R. FUENTES, C. TEIXIDÓ, J.L. RAMIREZ, N. FERRAN, F. SEBASTIÁN, R. ROSELL ( <i>Girona; Barcelona; Badalona, Spain</i> ) .....	4871
Palliative Pelvic Exenteration for Pelvic Recurrence Invading the Sciatic Foramen with Chronic Cutaneous Perineal Fistula after Radical Surgery for Cervical Cancer: A Case Report. N. BACALBASA, I. BAILESCU ( <i>Bucharest, Romania</i> ) .....	4877
5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method. Y. YOSHIDA, K. OGURA, A. HIRATSUKA, N. AISU, T. YAMADA, D. KOJIMA, S. TANIMURA, K. OGATA, S. HARA, A. MOGI, Y. TAKAMATSU, K. TAMURA, H. MISHIMA, Y. YAMASHITA ( <i>Fukuoka; Tokyo; Nagakute, Japan</i> ) .....	4881
Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy. M. OHIRA, N. KUBO, Y. YAMASHITA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, K. HIRAKAWA ( <i>Osaka, Japan</i> ) .....	4889
Glasgow Prognostic Score as a Prognostic Clinical Marker in T4 Esophageal Squamous Cell Carcinoma. M. OHIRA, N. KUBO, G. MASUDA, Y. YAMASHITA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, K. HIRAKAWA ( <i>Osaka, Japan</i> ) .....	4897
Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation. Y. NIIBE, H. YAMASHITA, K. SEKIGUCHI, W. TAKAHASHI, K. SHIRAIISHI, K. OKUMA, A. TERAHARA, J. KAWAMORI, K. NAKAGAWA ( <i>Tokyo, Japan</i> ) .....	4903
Impact of Interstitial Changes on Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Cancer. T. YOSHITAKE, Y. SHIOYAMA, K. ASAI, K. NAKAMURA, T. SASAKI, S. OHGA, T. KAMITANI, T. YAMAGUCHI, K. OHSHIMA, K. MATSUMOTO, S. KAWANAMI, H. HONDA ( <i>Fukuoka; Tosu-shi, Saga, Japan</i> ) .....	4909
TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis. N. NOEL, J. COUTEAU, G. MAILLET, F. GOBET, F. D'ALOISIO, C. MINIER, C. PFISTER ( <i>Rouen; Le Havre, France</i> ) .....	4915

HPV-related Oropharyngeal Squamous Cell Carcinoma: p16INK4A Immunohistochemistry or HPV Genotyping? M. ORSARIA, S. MARZINOTTO, L. DE MARCHI, V. GIACOMARRA, S. BORIA, C. RUBINI, A.P. LONDERO, C. DI LORETO, L. MARIUZZI ( <i>Udine; Tolmezzo; Ancona; Monfalcone, Italy</i> ) .....	4733
Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis. A.-R. CHOI, M.-J. JUNG, J.-H. KIM, S. YOON ( <i>Gyeonggi-do, Republic of Korea</i> ).....	4741
Pro-apoptotic and Growth-inhibitory Effect of <i>IFN-β</i> -Overexpressing Canine Adipose Tissue-derived Mesenchymal Stem Cells Against Melanoma Cells. S.-M. HAN, C.-W. PARK, J.-O. AHN, S.-C. PARK, W.-S. JUNG, K.-W. SEO, J.-C. RA, S.-K. KANG, H.-W. LEE, H.-Y. YOUN ( <i>Seoul; Daejeon, Republic of Korea</i> ).....	4749
Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts. M. EMOTO, H. YOSHIHISA, K. YANO, B. CHOIJAMTS, H. TSUGU, K. TACHIBANA, M. AIZAWA ( <i>Sawara-ku; Jonan-ku, Fukuoka; Tama-ku, Kawasaki, Japan</i> ) ....	4757
Chemoprevention of Azoxymethane-induced Colonic Carcinogenesis in Balb/c mice Using a Modified Pectin Alginate Probiotic. F. ODUN-AYO, J. MELLEM, T. NAICKER, L. REDDY ( <i>KwaZulu-Natal; Cape Town, South Africa</i> ) .....	4765
Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells. W.-C. HSU, C.-N. CHENG, T.-W. LEE, J.-J. HWANG ( <i>Taipei; Taoyuan, Taiwan, ROC</i> ).....	4777
Angiotensin II Increases Cancer Stem Cell-like Phenotype in Lung Cancer Cells. S. TAWINWUNG, C. NINSONTIA, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	4789
Role of Hyaluronan and Glucose on 4-Methylumbelliferone-inhibited Cell Proliferation in Breast Carcinoma Cells. R. WANG, W. ZHOU, J. WANG, Y. LIU, Y. CHEN, S. JIANG, X. LUO, D.G. STUPACK, N. LUO ( <i>Tianjin, PR China; La Jolla, CA, USA</i> ) .....	4799
Q192R and L55M Polymorphisms of Paraoxonase 1 Gene in Chronic Myelogenous Leukemia and Chronic Lymphocytic Leukemia. A.G. TOMATIR, S. PEHLIVAN, H. HAYDAROĞLU SAHIN, S. OGUZKAN BALCI, S. BUDEYRI, M. PEHLIVAN ( <i>Denizli; Istanbul; Gaziantep, Turkey</i> ).....	4807
<i>Clinical Studies</i>	
Predicting Outcome in Colonoscopic High-risk Surveillance. A.M. FORSBERG, E. HAGEL, E. JARAMILLO, C.A. RUBIO, E. BJÖRCK, A. LINDBLOM ( <i>Stockholm, Sweden</i> ) .....	4813
A Case of Focal Small-cell Neuroendocrine Carcinoma in the Vicinity of the Extrahepatic Bile Duct, Adjacent to an Extensive Biliary Intraepithelial Neoplasm: A Diagnostic Challenge with Major Clinical Implications. B. AIGNER, P. KORNPAT, H. SCHÖLLNAST, A.-K. KASPAREK, H.-J. MISCHINGER, J. HAYBAECK ( <i>Graz, Austria</i> ) .....	4821
Prognostic Impact of ALDH1 Expression in Transitional Cell Carcinoma of the Renal Pelvis. J. LIU, J. JIN, Y. YANG, W. HAN, W. YU, C. SHEN, N. ZHANG, P. DU, Q. ZHAO, S. WANG, X. TANG ( <i>Beijing, PR China</i> ) .....	4829
Sporadic Burkitt Lymphoma Mimicking Osteomyelitis of the Mandible Revealing Clinically Unsuspected HIV Infection. S. SIVOLELLA, G. RIZZO, M. VALENTE, F. LUMACHI ( <i>Padova, Italy</i> ) .....	4837
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. R.K. DANDAMUDI, S. ASLAM, N. WALJI, A. EL-MODIR, I. FERNANDO ( <i>Birmingham, UK</i> ) .....	4841

Suppressor microRNA-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma. K. HARADA, Y. BABA, T. ISHIMOTO, K. KOSUMI, R. TOKUNAGA, D. IZUMI, M. OHUCHI, K. NAKAMURA, Y. KIZOYUMI, J. KURASHIGE, S. IWAGAMI, Y. MIYAMOTO, Y. SAKAMOTO, N. YOSHIDA, E. OKI, M. WATANABE, H. BABA ( <i>Kumamoto; Higashi-ku, Fukuoka; Koto-ku, Tokyo, Japan</i> ) .....	4617
WNT16-expressing Acute Lymphoblastic Leukemia Cells are Sensitive to Autophagy Inhibitors after ER Stress Induction. M. VERRAS, I. PAPANDREOU, N.C. DENKO ( <i>Rio, Greece; Columbus, OH, USA</i> ) ....	4625
Angiopoietin-like Protein 2 as a Predictor of Early Recurrence in Patients After Curative Surgery for Gastric Cancer. T. SHIMURA, Y. TOIYAMA, K. TANAKA, S. SAIGUSA, T. KITAJIMA, S. KONDO, M. OKIGAMI, H. YASUDA, M. OHI, T. ARAKI, Y. INOUE, K. UCHIDA, Y. MOHRI, M. KUSUNOKI ( <i>Tsu, Mie, Japan</i> ) .....	4633
Surgically-Induced Multi-organ Metastasis in an Orthotopic Syngeneic Imageable Model of 4T1 Murine Breast Cancer. Y. ZHANG, N. ZHANG, R.M. HOFFMAN, M. ZHAO ( <i>San Diego, CA, USA</i> ) .....	4641
A Color-coded Imageable Syngeneic Mouse Model of Stromal-cell Recruitment by Metastatic Lymphoma. T. MATSUMOTO, A. SUETSUGU, Y. SHIBATA, N. NAKAMURA, H. AOKI, T. KUNISADA, H. TSURUMI, M. SHIMIZU, R.M. HOFFMAN ( <i>Gifu, Japan; San Diego, CA, USA</i> ) .....	4647
Comparison of GFP-Expressing Imageable Mouse Models of Human Esophageal Squamous Cell Carcinoma Established in Various Anatomical Sites. T. HU, H. QI, P. LI, G. ZHAO, Y. MA, Q. HAO, C. GAO, Y. ZHANG, C. WANG, M. YANG, R.M. HOFFMAN, P. CHEN, Z. DONG ( <i>Zhengzhou; Beijing, P.R. China; San Diego, CA, USA</i> ) .....	4655
Uterine Leiomyosarcoma Tumorigenesis in <i>Lmp2</i> -deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1. T. HAYASHI, A. HORIUCHI, K. SANO, N. YAEGASHI, I. KONISHI ( <i>Matsumoto, Nagano; Sendai, Miyagi; Kyoto; Tokyo, Japan</i> ) .....	4665
Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats. K. HOTTA, J. UHEYAMA, Y. TATSUMI, I. TSUKIYAMA, Y. SUGIURA, H. SAITO, K. MATSUURA, T. HASEGAWA ( <i>Nagakute; Nagoya, Aichi, Japan</i> ) .....	4681
Contribution of X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 3 ( <i>XRCC3</i> ) Genotype to Leiomyoma Risk. W.-S. CHANG, C.-W. TSAI, J.-Y. WANG, T.-H. YING, T.-S. HSIAO, C.-L. CHUANG, T.-C. YUEH, C.-H. LIAO, C.-M. HSU, S.-P. LIU, C.-L. GONG, C.-H. TSAI, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	4691
3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. C. MAYR, A. WAGNER, A. STOECKLINGER, M. JAKAB, R. ILLIG, F. BERR, M. PICHLER, P. DI FAZIO, M. OCKER, D. NEUREITER, T. KIESSLICH ( <i>Salzburg; Graz, Austria; Marburg, Germany</i> ) .....	4697
The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of Cancer. S. XIAN, N.N. PARAYATH, H. NEHOFF, N.M. GILES, K. GREISH ( <i>Dunedin, New Zealand</i> ) .....	4707
Vessel and Mast Cell Densities in Sporadic and Syndrome-associated Peripheral Nerve Sheath Tumors. R.E. FRIEDRICH, U. NABER, M. GLATZEL, C. HAGEL ( <i>Hamburg, Germany</i> ) .....	4713
Apoptotic Effects of Novel Dithiocarbamate Analogs of Emetine in Prostate Cancer Cell Lines. Z.D. BAMJI, K.N. WASHINGTON, E. AKINBOYE, O. BAKARE, Y.M. KANAAN, R.L. COPELAND JR ( <i>Washington, DC, USA</i> ) .....	4723